GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » Total Inventories

Evotec SE (WBO:EVT) Total Inventories : €30.9 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Evotec SE Total Inventories?

Evotec SE's total inventories for the quarter that ended in Dec. 2023 was €30.9 Mil. Evotec SE's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was €31.4 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Evotec SE's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was €-2.41.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Evotec SE's Days Inventory for the three months ended in Dec. 2023 was 17.51.

Inventory Turnover measures how fast the company turns over its inventory within a year. Evotec SE's Inventory Turnover for the quarter that ended in Dec. 2023 was 5.21.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Evotec SE's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.16.


Evotec SE Total Inventories Historical Data

The historical data trend for Evotec SE's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Total Inventories Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.75 13.59 25.79 29.83 30.89

Evotec SE Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.87 29.83 32.61 31.91 30.89

Evotec SE Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Evotec SE  (WBO:EVT) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Evotec SE's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(616.871+0.75 * 98.396+0.5 * 30.89-1132.561
-0-0)/176.936
=-2.41

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Evotec SE's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=31.398/163.646*365 / 4
=17.51

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Evotec SE's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=163.646 / 31.398
=5.21

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Evotec SE's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=31.398 / 201.313
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Evotec SE Total Inventories Related Terms

Thank you for viewing the detailed overview of Evotec SE's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE (WBO:EVT) Business Description

Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Evotec SE (WBO:EVT) Headlines